(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China.

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...

1. Rule 8 of the CGST Rules, 2017 has been amended to provide that an applicant can be identified on the common portal, based on data analysis and risk parameters for Biometric-based Aadhaar ...

If the Superior Court rejects the application to raise it to the Supreme Court, GSK and the other defendants ... and it was also sold in generic form by several other producers.

It has also been sold in generic form by several other producers, some of which have also been named in litigation, including Boehringer Ingelheim, Pfizer, and Johnson & Johnson. GSK's settlement ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 ...

Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for 2024.

After hours: 7:53:31 p.m. EST ...

CVs and/or application requests sent via email will not be answered ... Occasionally, some roles may still require candidates to apply by completing a Personal History Form (PHF) word document and ...